Keyphrases
Insulin-like Growth Factor 2 (IGF2)
100%
Pancreatic Cancer
100%
Mannose-6-phosphate
42%
IGF-II Receptor
35%
Multivalent
21%
Insulin-like
14%
Pancreatic Cancer Cells
14%
Growth Factors
14%
Insulin-like Growth Factor 1 Receptor (IGF1R)
14%
Genetically Engineered Mouse Models
7%
Monovalent Cations
7%
Localized Disease
7%
Orthotopic Transplantation
7%
Cell Division
7%
Mitogenic Signaling
7%
Tumor Development
7%
Pancreatic Cancer Cell Lines
7%
Cancer Causes
7%
Cargo
7%
5-year Survival
7%
Spontaneous Model
7%
Receptor-based
7%
Nude Mice
7%
Human Pancreatic Cancer Cells
7%
Ligand Trap
7%
PDAC Therapy
7%
Insulin Receptor
7%
Specific Intent
7%
4-fold
7%
In Vitro Tumor Models
7%
Cancer Cell Growth
7%
Cancer Mortality
7%
Cell Survival
7%
Pancreatic Ductal Adenocarcinoma
7%
Isoform A
7%
Survival Signaling
7%
Mitogenesis
7%
Gemcitabine
7%
Xenograft
7%
Lysosomal Enzymes
7%
Conventional Chemotherapy
7%
Metastatic Disease
7%
IGF2R
7%
Targeting Strategies
7%
Capan-1
7%
Systemic Administration
7%
Etiology
7%
Pericellular
7%
Receptor-mediated
7%
Novel Therapies
7%
Binding Site
7%
Core Pathways
7%
Receptor Isoforms
7%
Tumor Growth
7%
Tumor
7%
Medicine and Dentistry
Somatomedin B
100%
Pancreas Cancer
100%
Receptor
53%
Mannose 6 Phosphate
46%
Pancreatic Ductal Adenocarcinoma
38%
Malignant Neoplasm
23%
Somatomedin
15%
Neoplasm
15%
Internalization
15%
Cancer Cell
15%
Cell Survival
7%
Pancreatic Cancer Cell Line
7%
Binding Site
7%
Pancreas Adenocarcinoma
7%
Systemic Administration
7%
Somatomedin B Receptor
7%
Tumor Progression
7%
Signal Transduction
7%
Gemcitabine
7%
Somatomedin C Receptor
7%
Cell Division
7%
Tumor Model
7%
Lysosome Enzyme
7%
Xenograft
7%
Mitogenesis
7%
Metastatic Carcinoma
7%
In Vitro
7%
Five-Year Survival Rate
7%
Cancer Growth
7%
Cancer Mortality
7%
Insulin Receptor
7%
Orthotopic Transplantation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Somatomedin B
100%
Pancreas Cancer
100%
Receptor
53%
Mannose 6 Phosphate
46%
Malignant Neoplasm
23%
Somatomedin
15%
Neoplasm
15%
Somatomedin B Receptor
7%
Systemic Administration
7%
Tumor Model
7%
Survival Rate
7%
Tumor Growth
7%
Lysosome Enzyme
7%
Gemcitabine
7%
Somatomedin C Receptor
7%
Nude Mouse
7%
Insulin Receptor
7%
Pancreas Adenocarcinoma
7%
Binding Site
7%
Chemotherapy
7%
Metastasis
7%
Cancer Growth
7%
Cancer Mortality
7%
Mouse Model
7%
Genetically Engineered Mouse Strain
7%